Flow cytometric immunophenotyping of regulatory T cells in chronic lymphocytic leukemia: Comparative assessment of various markers and use of novel antibody panel with CD127 as alternative to transcription factor FoxP3

Leukemia and Lymphoma

Volumn 54, Issue 4, 2013, Pages 778-789

  Dasgupta, Alakananda ^a   Mahapatra, Manoranjan ^a   Saxena, Renu ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

CD127low ; CD25high; CD4; Chronic lymphocytic leukemia; FoxP3; Limited antibody panel; Novel; Regulatory T cell

Indexed keywords

ANTINEOPLASTIC AGENT; INTERLEUKIN 7 RECEPTOR; TRANSCRIPTION FACTOR FOXP3;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CD4+ T LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DISEASE SEVERITY; FLOW CYTOMETRY; GOLD STANDARD; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; INDIAN; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SENSITIVITY AND SPECIFICITY;

AGED; ANTIGENS, CD4; ANTIGENS, SURFACE; CASE-CONTROL STUDIES; FEMALE; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOPHENOTYPING; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; INTERLEUKIN-7 RECEPTOR ALPHA SUBUNIT; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; NEOPLASM STAGING; T-LYMPHOCYTES, REGULATORY;

EID: 84879522118     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.730614     Document Type: Article

References (38)

1. Beyer M, Kochanek M, Darabi K, et al. Reduced frequencies and suppressive function of CD4 + CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005; 106: 2018-2025.
2. Giannopoulos K, Schmitt M, Kowal M, et al. Characterization of regulatory T cells in patients with B-cell chronic lymphocytic leukemia. Oncol Rep 2008; 20: 677-682.
3. Deutsch V, Perry C, Polliack A. E xpansion of regulatory T cells in B chronic lymphocytic leukemia: Enhanced " brakes " on host immunity. Leuk Lymphoma 2009; 50: 687-688.
4. Jak M, Mous R, Remmerswaal E BM, et al. Enhanced formation and survival of CD4 + CD25hi Foxp3 + T-cells in chronic lymphocytic leukemia. Leuk Lymphoma 2009; 50: 788-801.
5. D' Arena G, Laurenti L, Minervini MM, et al. Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease. Leuk Res 2011; 35: 363-368.
6. Diehl LF, Karnell LH, Menck HR. The American College of Surgeons Commission on Cancer and the American Cancer Society. The National Cancer Data Base report on age, gender, treatment, and outcomes of patients with chronic lymphocytic leukemia. Cancer 1999; 86: 2684-2692.
7. Agrawal N, Naithani R, Mahapatra M, et al. Chronic lymphocytic leukemia in India-a clinico-hematological profi le. Hematology 2007; 12: 229-233.
8. Naresh KN, Agarwal B, Nathwani BN, et al. Use of the World Health Organization (WHO) classifi cation of non-Hodgkin's lymphoma in Mumbai, India: A review of 200 consecutive cases by a panel of fi ve expert hematopathologists. Leuk Lymphoma 2004; 45: 1569-1577.
9. Bhutani M, Vora A, Kumar L, et al. Lympho-hemopoietic malignancies in India. Med Oncol 2002; 19: 141-150.
10. Nair CN, Chougule A, Dhond S, et al. Trisomy 12 in chronic lymphocytic leukemia-geographical variation. Leuk Res 1998; 22: 313-317.
11. Montserrat E, Rozman C. C hronic lymphocytic leukemia: Present status. Ann Oncol 1995; 6: 219-235.
12. Gershon R K, Kondo K. I nfectious immunological tolerance. Immunology 1971; 21: 903-914.
13. Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155: 1151-1164.
14. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299: 1057-1061.
15. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4 + CD25 + regulatory T cells. Nat Immunol 2003; 4: 330-336.
16. Rouse BT. Regulatory T cells in health and disease. J Intern Med 2007; 262: 78-95.
17. Beyer M, Schultze JL. Regulatory T cells in cancer. Blood 2006; 108: 804-811.
18. Franzke A, Hunger JK, Dittmar KEJ, et al. Regulatory T-cells in the control of immunological diseases. Ann Hematol 2006; 85: 747-758.
19. Baecher-Allan C, Brown JA, Freeman GJ, et al. CD4+ CD25high regulatory cells in human peripheral blood. J Immunol 2001; 167: 1245-1253.
20. Liu W, Putnam AL, Xu-Yu Z, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4 + T reg cells. J Exp Med 2006; 203: 1701-1711.
21. Seddiki N, Santner-Nanan B, Martinson J, et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006; 203: 1693-1700.
22. Sakaguchi S, Sakaguchi N, Shimizu J, et al. Immunologic tolerance maintained by CD25 + CD4 + regulatory T cells: Their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001; 182: 18-32.
23. Varona R, Cadenas V, Lozano M, et al. CCR6 regulates the function of alloreactive and regulatory CD4 + T cells during acute graft-versushost disease. Leuk Lymphoma 2006; 47: 1469-1476.
24. Coghill J M, Carlson M J, Moran T P, et al. The biology and therapeutic potential of natural regulatory T-cells in the bone marrow transplant setting. Leuk Lymphoma 2008; 49: 1860-1869.
25. Onizuka S, Tawara I, Shimizu J, et al. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 1999; 59: 3128-3133.
26. Lee N-R, Song E-K, Jang KY, et al. Prognostic impact of tumor infi ltrating FOXP3 positive regulatory T cells in Diffuse large B-cell lymphoma at diagnosis. Leuk Lymphoma 2008; 49: 247-256.
27. Szczepanski MJ, Szajnik M, Czystowska M, et al. Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia. Clin Cancer Res 2009; 15: 3325-3332.
28. Wang X, Zheng J, Liu J, et al. Increased population of CD4 (+) CD25(high), regulatory T cells with their higher apoptotic and proliferating status in peripheral blood of acute myeloid leukemia patients. Eur J Haematol 2005; 75: 468-476.
29. Beyer M, Kochanek M, Giese T, et al. In vivo peripheral expansion of naive CD4 + CD25high FoxP3 + regulatory T cells in patients with multiple myeloma. Blood 2006; 107: 3940-3949.
30. Mittal S, Marshall NA, Duncan L, et al. Local and systemic induction of CD4 + CD25 + regulatory T-cell population by non-Hodgkin lymphoma. Blood 2008; 111: 5359-5370.
31. Rojas J M, Wang L, Owen S, et al. Naturally occurring CD4+CD25 + FOXP3 + T-regulatory cells are increased in chronic myeloid leukemia patients not in complete cytogenetic remission and can be immunosuppressive. Exp Hematol 2010; 38: 1209-1218.
32. Weiss L, Melchardt T, Egle A, et al. Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia. Cancer 2011; 117: 2163-2169.
33. Marshall NA, Christie LE, Munro LR, et al. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 2004; 103: 1755-1762.
34. Yang Z -Z, Novak A J, Stenson M J, et al. Intratumoral CD4+ CD25+regulatory T-cell-mediated suppression of infi ltrating CD4 + T cells in B-cell non-Hodgkin lymphoma. Blood 2006; 107: 3639-3646.
35. Perry C, Herishanu Y, Hazan-Halevy I, et al. Reciprocal changes in regulatory T cells and Th 17 helper cells induced by exercise in patients with chronic lymphocytic leukemia. Leuk Lymphoma 2012; 53: 1807-1810.
36. Lutsiak M EC, Semnani R T, D e Pascalis R, et al. Inhibition of CD4 (+) 25 + T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005; 105: 2862-2868.
37. Giannopoulos K, Dmoszynska A, Kowal M, et al. Th alidomide exerts distinct molecular antileukemic Effects and combined thalidomide/fl udarabine therapy is clinically effective in high-risk chronic lymphocytic leukemia. Leukemia 2009; 23: 1771-1778.
38. Curiel T J, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 942-949. Science and Technology), Government of India